Key result
Mechanical valves show no survival benefit over bioprosthetic valves in tricuspid replacement, with more complications.
Why the study?
The optimal choice between mechanical and bioprosthetic valves for tricuspid valve replacement in Chinese patients remains controversial, with a lack of large-sample evidence.
Does mechanical valve replacement improve early mortality, long-term survival, or reoperation rates compared to bioprosthetic valves in Chinese patients undergoing tricuspid valve replacement?
Meta-Analysis (n=1,504)
Yes
Does mechanical valve replacement improve early mortality, long-term survival, or reoperation rates compared to bioprosthetic valves in Chinese patients undergoing tricuspid valve replacement?
In Chinese patients requiring tricuspid valve replacement, mechanical and bioprosthetic valves yield comparable survival and reoperation rates, but mechanical valves are associated with a markedly higher risk of bleeding and thromboembolism.
Answers are grounded in this paper and cite their sources.
No survival benefit with mechanical valves but higher bleeding and thromboembolism risks; leaves open randomized trials to guide selection.
Background: Tricuspid valve replacement (TVR) is a critical intervention for severe tricuspid valve disease but carries high perioperative mortality. The optimal choice between mechanical and bioprosthetic valves remains controversial, and large-sample evidence specific to the Chinese population is lacking. This study aimed to systematically evaluate the clinical efficacy and safety of mechanical versus bioprosthetic valves in Chinese patients undergoing TVR. Methods: <50%; otherwise, a random-effects model was applied. Results: Eight retrospective cohort studies (1,504 patients: 537 mechanical, 967 bioprosthetic) were included. No statistically significant differences emerged between mechanical and bioprosthetic valves in early mortality [risk ratio (RR) 0.70, 95% confidence interval (CI): 0.48-1.02, P=0.06], long-term survival (HR 1.02, 95% CI: 0.57-1.84, P=0.94), or reoperation rate (RR 1.12, 95% CI: 0.61-2.05, P=0.72). Mechanical valves were associated with significantly higher risks of thromboembolic events (RR 2.09, 95% CI: 1.06-4.13, P=0.03) and bleeding events (RR 4.89, 95% CI: 3.12-7.72, P<0.00001). The rate of pacemaker implantation did not differ significantly between groups (RR 0.82, 95% CI: 0.44-1.53, P=0.54). Conclusions: In Chinese TVR patients, overall early and long‑term survival as well as reoperation rates do not differ significantly between mechanical and bioprosthetic valves when analyzed across heterogeneous populations. However, this finding does not imply that valve type is unimportant for individual patients. However, mechanical valves significantly increase postoperative thromboembolic and bleeding complications. Clinical decision-making should be individualized, considering patient age, life expectancy, anticoagulation adherence, and bleeding risk. For Chinese patients with good life expectancy and reliable anticoagulation access, mechanical valves remain an option; for those with poor adherence or high bleeding risk, bioprosthetic valves may be safer.
No takes yet. Share an insight, caveat, or question.
Song et al. (2026) conducted a meta-analysis in Severe tricuspid valve disease requiring replacement (n=1,504). Mechanical valve replacement vs. Bioprosthetic valve replacement was evaluated on Early mortality (30-day or in-hospital mortality) (RR 0.70, 95% CI 0.48-1.02, p=0.06). Mechanical valves showed no significant difference in early mortality, long-term survival, or reoperation rates compared to bioprosthetic valves in Chinese patients undergoing tricuspid valve replacement, but significantly increased thromboembolic and bleeding events.
Synapse has enriched 10 related papers. Consider them for comparative context: